Literature DB >> 11311630

Safety and predictability of laser in situ keratomileusis enhancement by flap reelevation in high myopia.

A Brahma1, C N McGhee, J P Craig, A D Brown, K H Weed, J McGhee, R Brown.   

Abstract

PURPOSE: To evaluate the safety and predictability of laser in situ keratomileusis (LASIK) retreatment following primary procedures for high myopia and astigmatism.
SETTING: Corneal Diseases and Excimer Laser Research Unit, Department of Ophthalmology, University of Dundee, Dundee, United Kingdom.
METHODS: This prospective observational study of retreatment comprised a cohort of 109 eyes having primary LASIK for high myopia and astigmatism with a spherical equivalent (SE) of -9.70 diopters (D) +/- 4.06 (SD). Twenty-four eyes (22%) with an initial myopic SE of -9.83 +/- 3.50 D, a comparable subset of the entire group (P < .05), had retreatment for residual myopia (-3.02 +/- 2.17 D) to improve uncorrected visual acuity (UCVA) by reelevating the corneal flap and ablating the stromal bed.
RESULTS: The mean follow-up after retreatment was 12.8 +/- 5.1 months (range 1.5 to 24 months; 19 eyes >/=6 months, 13 eyes > or = 12 months). The mean myopic SE was reduced to +0.53 +/- 0.62 D at 1 week, +0.05 +/- 0.50 D at 1 month, +0.30 +/- 0.50 D at 6 months, and +0.18 +/- 0.42 D at the latest follow-up, 12.8 months. At the latest review, 62% of eyes were within +/-0.50 D of emmetropia and 100% were within +/-1.00 D. The mean refraction did not alter statistically between 1 week and subsequent times. The mean UCVA improved from 6/30 prior to retreatment to 6/9 at the latest follow-up. Uncorrected visual acuity of 6/6 or better, 6/9 or better, and 6/12 or better was achieved by 33.0%, 75.0%, and 95.8% of eyes, respectively. No significant complications that led to a loss of best corrected visual acuity were encountered, although retreatment procedures were more uncomfortable than primary procedures and self-limiting; epithelial ingrowth that did not threaten vision was common, and 2 patients complained of nighttime visual symptoms.
CONCLUSIONS: Retreatment of residual myopia by reelevating the flap was relatively safe and predictable, with a low risk of sight-threatening complications. However, longer term studies may be required to detect late complications.

Entities:  

Mesh:

Year:  2001        PMID: 11311630     DOI: 10.1016/s0886-3350(01)00765-9

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  6 in total

1.  Differences between Goldmann Applanation Tonometry and Dynamic Contour Tonometry following Trabeculectomy.

Authors:  Efstathios T Detorakis; Emilia Grammenandi; Ioannis G Pallikaris; Miltiadis K Tsilimbaris
Journal:  J Ophthalmol       Date:  2010-07-13       Impact factor: 1.909

2.  Analysis of the visual and refractive outcome following laser in situ keratomileusis (LASIK) retreatment over a four-year follow-up period.

Authors:  Ayman Saeed; Maeve O'Doherty; John O'Doherty; Michael O'Keefe
Journal:  Int Ophthalmol       Date:  2007-03-24       Impact factor: 2.029

3.  Wavefront-optimized surface retreatments of refractive error following previous laser refractive surgery: a retrospective study.

Authors:  Kevin M Broderick; Rose K Sia; Denise S Ryan; Richard D Stutzman; Michael J Mines; Travis C Frazier; Mark F Torres; Kraig S Bower
Journal:  Eye Vis (Lond)       Date:  2016-02-11

4.  Photorefractive Keratectomy for Residual Myopia after Myopic Laser In Situ Keratomileusis.

Authors:  Kamal A M Solaiman; Sameh M Fouda; Ashraf Bor'i; Haitham Y Al-Nashar
Journal:  J Ophthalmol       Date:  2017-01-12       Impact factor: 1.909

5.  Results of laser enhancement for residual myopia after primary laser in situ keratomileusis.

Authors:  Mahfouth A Bamashmus; Hisham A Al-Akhlee; Yasmin A Al-Azani; Najeeb A Al-Kershy
Journal:  Taiwan J Ophthalmol       Date:  2019-11-07

6.  Reversal of Myopic Correction for Patients Intolerant to LASIK.

Authors:  Amr A Gab-Alla
Journal:  J Ophthalmol       Date:  2021-12-15       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.